Skip to content
Screener

BioMarin Pharmaceuticals BMRN ALDURAZYME — Total revenues

Other product segments

VOXZOGO
$252.53M+14.1%
VIMIZIM
$194.37M-9.8%
NAGLAZYME
$135.26M+5.0%
PALYNZIQ
$135.17M+27.6%
GALAFOLD
$105.75M—
BRINEURA
$51.37M+5.5%
POMBILITI + OPFOLDA
$30.26M—
KUVAN
$24.44M-9.6%
ROCTAVIAN
$11.71M+27.3%
Royalty and other revenues
$5.32M-57.2%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
PALYNZIQ135,167105,938224,725199,207
GALAFOLD(1)105,748—105,748—
BRINEURA51,37048,69298,47489,054
ALDURAZYME43,53956,43780,281105,414
POMBILITI + OPFOLDA(1)30,258—30,258—
KUVAN24,44427,03448,32452,170
ROCTAVIAN11,7139,19914,34919,709
Total net product revenues984,393812,9821,744,4711,547,626

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's ALDURAZYME — total revenues?
BioMarin Pharmaceuticals (BMRN) reported ALDURAZYME — total revenues of $43.54M in Q2 2026.
How has BioMarin Pharmaceuticals's ALDURAZYME — total revenues changed year-over-year?
BioMarin Pharmaceuticals's ALDURAZYME — total revenues decreased by 22.9% year-over-year, from $56.44M to $43.54M.
What is the long-term trend for BioMarin Pharmaceuticals's ALDURAZYME — total revenues?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's ALDURAZYME — total revenues has grown at a 14.2% compound annual growth rate (CAGR), from $122.77M to $208.51M.
What does ALDURAZYME — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific therapeutic product within a defined business segment. It reflects the market demand and commercial performance of the drug, including contributions from joint ventures or direct marketing efforts. This figure is a primary indicator of the product's lifecycle stage and its contribution to the company's overall top-line growth.

Ask your AI about BioMarin Pharmaceuticals's aldurazyme — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude